Merus (MRUS) Stock Forecast & Price Target

Compare

513 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRUS Analyst Ratings

Hold

0 Buy

14 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Merus

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRUS Stock 12 Month Forecast

Average Price Target

$97.00

▼(-0.01% Downside)

Based on 14 Wall Street analysts offering 12 month price targets for Merus in the last 3 months. The average price target is $97.00 with a high forecast of $97.00 and a low forecast of $97.00. The average price target represents a -0.01% change from the last price of $97.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","53":"$53","68":"$68","83":"$83","98":"$98"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$97.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$97.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":97,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$97.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,53,68,83,98],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.94,96.02153846153846,96.10307692307693,96.18461538461538,96.26615384615384,96.34769230769231,96.42923076923077,96.51076923076923,96.59230769230768,96.67384615384616,96.75538461538461,96.83692307692307,96.91846153846154,{"y":97,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.94,96.02153846153846,96.10307692307693,96.18461538461538,96.26615384615384,96.34769230769231,96.42923076923077,96.51076923076923,96.59230769230768,96.67384615384616,96.75538461538461,96.83692307692307,96.91846153846154,{"y":97,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.94,96.02153846153846,96.10307692307693,96.18461538461538,96.26615384615384,96.34769230769231,96.42923076923077,96.51076923076923,96.59230769230768,96.67384615384616,96.75538461538461,96.83692307692307,96.91846153846154,{"y":97,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.05,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.66,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.86,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.94,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$97.00

Average Price Target$97.00

Lowest Price Target$97.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Venezia

Alliance Global Partners

$97

Hold

-0.01%

Downside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Merus (NASDAQ: MRUS)We maintain our Neutral rang and $97.00 PT.

Etzer Darout

Barclays

$97

Hold

-0.01%

Downside

Reiterated

11/04/25

Barclays Sticks to Its Hold Rating for Merus (MRUS)

Eva Fortea Verdejo

Wells Fargo

$97

Hold

-0.01%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Merus (NASDAQ: MRUS)

Matt Phipps

William Blair

Hold

―

Reiterated

11/03/25

Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline

John Newman

Canaccord Genuity

$97

Hold

-0.01%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Vanda (NASDAQ: VNDA) and Travere Therapeutics (NASDAQ: TVTX)

Asthika Goonewardene

Truist Financial

$97

Hold

-0.01%

Downside

Reiterated

11/03/25

Truist Financial Reaffirms Their Hold Rating on Merus (MRUS)

Ami Fadia

Needham

Hold

―

Reiterated

10/24/25

Cautious Hold Rating on Merus: Promising Efficacy in CRC Amidst Limited Data

Evan Seigerman

BMO Capital

$97

Hold

-0.01%

Downside

Reiterated

10/24/25

Cautious Hold Rating on Merus Due to Mixed Efficacy Data and Transaction Expectations

Andrew Berens

Leerink Partners

$95→$97

Hold

-0.01%

Downside

Downgraded

10/07/25

Merus downgraded to Market Perform from Outperform at LeerinkMerus downgraded to Market Perform from Outperform at Leerink

Charles Zhu

LifeSci Capital

$97

Hold

-0.01%

Downside

Reiterated

10/04/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (NASDAQ: MRUS) and Upstream Bio, Inc. (NASDAQ: UPB)

Yigal Nochomovitz

Citi

$101→$97

Hold

-0.01%

Downside

Downgraded

09/30/25

Merus (MRUS) was downgraded to a Hold Rating at Citi

David Dai

UBS

$72→$97

Hold

-0.01%

Downside

Downgraded

09/30/25

Hold Rating on Genmab's Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential

Michael Schmidt

Guggenheim

$109→$97

Hold

-0.01%

Downside

Downgraded

09/29/25

Merus downgraded to Neutral from Buy at GuggenheimMerus downgraded to Neutral from Buy at Guggenheim

Andres Y. Maldonado

H.C. Wainwright

$85→$97

Hold

-0.01%

Downside

Downgraded

09/29/25

Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$112

Buy

15.45%

Upside

Initiated

09/17/25

Roth MKM Initiates a Buy Rating on Merus (MRUS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Venezia

Alliance Global Partners

$97

Hold

-0.01%

Downside

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Merus (NASDAQ: MRUS)We maintain our Neutral rang and $97.00 PT.

Etzer Darout

Barclays

$97

Hold

-0.01%

Downside

Reiterated

11/04/25

Barclays Sticks to Its Hold Rating for Merus (MRUS)

Eva Fortea Verdejo

Wells Fargo

$97

Hold

-0.01%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV) and Merus (NASDAQ: MRUS)

Matt Phipps

William Blair

Hold

―

Reiterated

11/03/25

Cautious Hold Rating on Merus Amid Genmab Acquisition Uncertainty and Promising Pipeline

John Newman

Canaccord Genuity

$97

Hold

-0.01%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Vanda (NASDAQ: VNDA) and Travere Therapeutics (NASDAQ: TVTX)

Asthika Goonewardene

Truist Financial

$97

Hold

-0.01%

Downside

Reiterated

11/03/25

Truist Financial Reaffirms Their Hold Rating on Merus (MRUS)

Ami Fadia

Needham

Hold

―

Reiterated

10/24/25

Cautious Hold Rating on Merus: Promising Efficacy in CRC Amidst Limited Data

Evan Seigerman

BMO Capital

$97

Hold

-0.01%

Downside

Reiterated

10/24/25

Cautious Hold Rating on Merus Due to Mixed Efficacy Data and Transaction Expectations

Andrew Berens

Leerink Partners

$95→$97

Hold

-0.01%

Downside

Downgraded

10/07/25

Merus downgraded to Market Perform from Outperform at LeerinkMerus downgraded to Market Perform from Outperform at Leerink

Charles Zhu

LifeSci Capital

$97

Hold

-0.01%

Downside

Reiterated

10/04/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (NASDAQ: MRUS) and Upstream Bio, Inc. (NASDAQ: UPB)

Yigal Nochomovitz

Citi

$101→$97

Hold

-0.01%

Downside

Downgraded

09/30/25

Merus (MRUS) was downgraded to a Hold Rating at Citi

David Dai

UBS

$72→$97

Hold

-0.01%

Downside

Downgraded

09/30/25

Hold Rating on Genmab's Acquisition of Merus Reflects Fair Valuation and Limited Upside Potential

Michael Schmidt

Guggenheim

$109→$97

Hold

-0.01%

Downside

Downgraded

09/29/25

Merus downgraded to Neutral from Buy at GuggenheimMerus downgraded to Neutral from Buy at Guggenheim

Andres Y. Maldonado

H.C. Wainwright

$85→$97

Hold

-0.01%

Downside

Downgraded

09/29/25

Hold Rating Given to Merus Amid Genmab Acquisition Reflecting Full Stock Valuation and Strategic Asset Integration

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$112

Buy

15.45%

Upside

Initiated

09/17/25

Roth MKM Initiates a Buy Rating on Merus (MRUS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Merus

1 Month

xxx

Success Rate

8/14 ratings generated profit

Average Return

+6.83%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +6.83% per trade.

3 Months

xxx

Success Rate

12/14 ratings generated profit

Average Return

+23.96%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +23.96% per trade.

1 Year

Tara BancroftTD Cowen

Success Rate

11/13 ratings generated profit

Average Return

+64.27%

reiterated a buy rating 5 months ago

Copying Tara Bancroft's trades and holding each position for 1 Year would result in 84.62% of your transactions generating a profit, with an average return of +64.27% per trade.

2 Years

xxx

Success Rate

14/14 ratings generated profit

Average Return

+132.13%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +132.13% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRUS Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRUS has received 0 Buy Ratings, 15 Hold Ratings, and 0 Sell Ratings. MRUS average Analyst price target in the past 3 months is 97.00.

Each month's total comprises the sum of three months' worth of ratings.

MRUS Financial Forecast

MRUS Earnings Forecast

Next quarter’s earnings estimate for MRUS is -$1.11 with a range of -$1.84 to $0.45. The previous quarter’s EPS was -$1.26. MRUS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MRUS has Performed in-line its overall industry.

MRUS Sales Forecast

Next quarter’s sales forecast for MRUS is $8.48M with a range of -$2.00M to $16.38M. The previous quarter’s sales results were $12.15M. MRUS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MRUS has Performed in-line its overall industry.

MRUS Stock Forecast FAQ

What is MRUS’s average 12-month price target, according to analysts?

Based on analyst ratings, Merus NV’s 12-month average price target is 97.00.

What is MRUS’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MRUS, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRUS a Buy, Sell or Hold?

Merus NV has a consensus rating of Hold which is based on 0 buy ratings, 14 hold ratings and 0 sell ratings.

What is Merus NV’s price target?

The average price target for Merus NV is 97.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $97.00 ,the lowest forecast is $97.00. The average price target represents -0.01% Decrease from the current price of $97.01.

What do analysts say about Merus NV?

Merus NV’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of MRUS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Merus (MRUS) Stock Forecast & Price Target

MRUS Analyst Ratings

MRUS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Merus

MRUS Analyst Recommendation Trends

MRUS Financial Forecast

MRUS Earnings Forecast

MRUS Sales Forecast

MRUS Stock Forecast FAQ

Detailed List of Analyst Forecasts